Saltar al contenido
Merck
Todas las fotos(1)

Documentos clave

Ver Toda la documentación

SML2673

Sigma-Aldrich

Deferasirox

≥98% (HPLC)

Sinónimos:

4-[3,5-bis(2-Hydroxyphenyl)-1H-1,2,4-triazol-1-yl]benzoic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización

Seleccione un Tamaño

10 MG
MXP 2,038.00
50 MG
MXP 8,243.00

MXP 2,038.00

Fecha estimada de envío13 de abril de 2025

Solicitar un pedido a granel
Todas las fotos(1)

Seleccione un Tamaño

Cambiar Vistas
10 MG
MXP 2,038.00
50 MG
MXP 8,243.00

About This Item

Fórmula empírica (notación de Hill):
C21H15N3O4
Número de CAS:
201530-41-8
Peso molecular:
373.36
MDL number:
MFCD09951804
UNSPSC Code:
12352200
NACRES:
NA.77

MXP 2,038.00

Fecha estimada de envío13 de abril de 2025

Solicitar un pedido a granel

assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

N2(N\C(=C4\C=CC=CC\4=O)\N\C\2=C3\C=CC=CC\3=O)c1ccc(cc1)C(=O)O

InChI

1S/C21H15N3O4/c25-17-7-3-1-5-15(17)19-22-20(16-6-2-4-8-18(16)26)24(23-19)14-11-9-13(10-12-14)21(27)28/h1-12,22-23H,(H,27,28)/b19-15-,20-16+

InChI key

FMSOAWSKCWYLBB-VBGLAJCLSA-N

¿Está buscando productos similares? Visita Guía de comparación de productos

Application

Deferasirox has been used as an iron chelator to test its effect on clofazimine mediated growth inhibition and rescue in Salmonella typhimurium.[1]

Biochem/physiol Actions

Deferasirox belongs to the N-substituted bis-hydroxyphenyl-triazole family of tridentate iron chelators.[2]
Deferasirox is an orally available iron chelator used clinically for reduction of chronic iron overload in diseases such as β-thalassemia.
Orally available iron chelator

pictograms

Exclamation markEnvironment
GHS07,GHS09

signalword

Warning

hcodes

H302,H400

Hazard Classifications

Acute Tox. 4 Oral - Aquatic Acute 1

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number
0000245905
0000198000
0000183094

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

Busque por un COA

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Kangna Cao et al.
European journal of clinical pharmacology, 76(1), 51-59 (2019-11-05)
Our aim was to evaluate the influence of genetic polymorphisms involved in the metabolism and transportation of deferasirox on deferasirox pharmacokinetics in the Chinese population. Thirty-eight healthy Chinese subjects were administered with a single dose of 20 mg kg-1 deferasirox.
Goldie Y L Lui et al.
Oncotarget, 6(22), 18748-18779 (2015-07-01)
Newer and more potent therapies are urgently needed to effectively treat advanced cancers that have developed resistance and metastasized. One such strategy is to target cancer cell iron metabolism, which is altered compared to normal cells and may facilitate their
Juan Daniel Díaz-García et al.
Nature reviews. Nephrology, 10(10), 574-586 (2014-07-23)
In 2005, the oral iron chelator deferasirox was approved by the FDA for clinical use as a first-line therapy for blood-transfusion-related iron overload. Nephrotoxicity is the most serious and frequent adverse effect of deferasirox treatment. This nephrotoxicity can present as
Kandice Mah et al.
Journal of pediatric hematology/oncology, 42(6), 391-397 (2020-04-15)
Individuals with hemoglobinopathy (sickle cell anemia and thalassemia major) are at risk for cardiac complications such as heart failure and cardiomyopathy. Diastolic dysfunction is known to precede systolic dysfunction in many cardiac diseases. This study sought to determine whether changes
Claudia Bollig et al.
The Cochrane database of systematic reviews, 8, CD007476-CD007476 (2017-08-16)
Thalassaemia is a hereditary anaemia due to ineffective erythropoiesis. In particular, people with thalassaemia major develop secondary iron overload resulting from regular red blood cell transfusions. Iron chelation therapy is needed to prevent long-term complications.Both deferoxamine and deferiprone are effective;
Ver todos los artículos relacionados

Questions

Reviews

No rating value

Active Filters

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico